Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).
The ability of trinitrophenylated tumor cells to stimulate syngeneic antitumor response has been tested in 3 different tumor-host systems: A. Trinitrophenylated and inactivated Moloney induced YAC tumor cells (YAC-TNP) were able to induce the production of cytotoxic antibodies in low responding A/J mice, while inactivated YAC tumor cells (YAC-In) failed to induce such a response. Furthermore, A mice which were injected with YAC-TNP rejected 103 viable YAC tumor cells at a higher frequency than those injected with YAC-In. B. Trinitrophenylated and inactivated Gross virus induced G-35 tumor cells or Monoloney induced LSTRA cells (both syngeneic in BALB/c mice) were as immunogenic as nonmodified inactivated tumor cells. About 50% of the immunized mice survived indefinitely after injection of 103 viable tumors. Fruthermore, spleen cells from mice primed with either modified or nonomodified G-35 cells responded in vitro to G-35 in a mixed leukocyte tumor interaction and generated specific cell-mediated cytotoxic activity to 51Cr-G-35 syngeneic tumors. However, the donors of the primed cells did not produce detectable cytotoxic antibodies to G-35. C. In vitro sensitization of C57B1 spleen cells by trinitrophenylated Mitomycin C treated syngeneic EL-4 generated a stronger cytotoxic response to EL-4 cells than obtained by sensitization with Mitomycin C treated EL-4 cells alone, The superiority of the sensitizing capacity of trinitrophenylated EL-4 was readily demonstrated in conditions which were suboptimal for nonmodified Mitomycin C treated tumor. Both theoretical and practical implications of these results are discussed.
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D002471:Cell Transformation, Neoplastic; D007109:Immunity; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008937:Mitomycins / Q000494:pharmacology; D008979:Moloney murine leukemia virus / Q000276:immunology; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology*; D009578:Nitrobenzenes / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000502:physiology; D014302:Trinitrobenzenesulfonic Acid / Q000494:pharmacology / Q000627:therapeutic use
D008937:Mitomycins; D009578:Nitrobenzenes; D014302:Trinitrobenzenesulfonic Acid